Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Liabilities from Discontinued Operations (2022 - 2024)

Arcadia Biosciences filings provide 3 years of Liabilities from Discontinued Operations readings, the most recent being 240000.0 for Q2 2024.

  • On a quarterly basis, Liabilities from Discontinued Operations changed N/A to 240000.0 in Q2 2024 year-over-year; TTM through Jun 2024 was 240000.0, a N/A change, with the full-year FY2023 number at 500000.0, up 1823.08% from a year prior.
  • Liabilities from Discontinued Operations hit 240000.0 in Q2 2024 for Arcadia Biosciences, down from 500000.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 500000.0 in Q4 2023 to a low of 26000.0 in Q4 2022.
  • Median Liabilities from Discontinued Operations over the past 3 years was 135500.0 (2023), compared with a mean of 199250.0.
  • The widest YoY moves for Liabilities from Discontinued Operations: up 1823.08% in 2023, down 1823.08% in 2023.
  • Arcadia Biosciences' Liabilities from Discontinued Operations stood at 26000.0 in 2022, then surged by 1823.08% to 500000.0 in 2023, then tumbled by 52.0% to 240000.0 in 2024.
  • The last three reported values for Liabilities from Discontinued Operations were 240000.0 (Q2 2024), 500000.0 (Q4 2023), and 31000.0 (Q3 2023) per Business Quant data.